Westminster, United States
TriSalus Life Sciences is an oncology company founded in 2009 that focuses on integrating novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. Their slogan "An immunotherapy company working to improve the lives of patients living with liver and pancreatic tumors" reflects their mission to make a positive impact on the lives of these patients. The company operates in the Biotechnology and Hardware industries and is based in the United States.
The latest milestone for TriSalus Life Sciences is the $23.50M Series E investment received on 09 November 2022. This substantial investment underscores the confidence that investors have in the company's innovative approach and the potential of their technology in addressing critical medical needs. The investors behind this funding round are yet to be announced, but this significant financial injection positions the company for further advancement and growth in their mission to improve patient outcomes.
Immugenia Inc.
